Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know

Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in its earnings estimates. This upgrade is significant as earnings estimate revisions are strongly correlated with near-term stock price movements, indicating a positive earnings outlook for DGX that could drive buying pressure. Analysts have steadily raised estimates for the medical laboratory operator, with the Zacks Consensus Estimate increasing 0.1% over the past three months, positioning DGX in the top 20% of Zacks-covered stocks and implying potential near-term stock appreciation.

Analysis

Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), a move primarily driven by positive revisions in its earnings estimates. Specifically, the Zacks Consensus Estimate for the fiscal year ending December 2025 has increased by 0.1% over the past three months, now standing at $9.70 per share. While the upward revision signals improving analyst sentiment, it is critical to note that this EPS forecast represents no year-over-year growth for the company. The investment thesis presented is based on the strong historical correlation between positive earnings estimate revisions and near-term stock price momentum, suggesting that this rating change could attract institutional buying and support the stock price. By achieving this rank, DGX is positioned within the top 20% of stocks covered by the Zacks system, highlighting it as a candidate for potential outperformance based on this quantitative factor rather than a significant shift in its fundamental growth outlook.

Key Decisions for Investors

• Investors could view the Zacks Rank #2 upgrade as a tactical, near-term positive signal, given the historical correlation between upward earnings revisions and stock price performance.
• It is crucial to balance this bullish signal against the underlying fundamental data, which projects flat year-over-year earnings for fiscal 2025 at $9.70 per share, indicating stable but not accelerating profitability.
• Consider the marginal nature of the catalyst, as the 0.1% increase in consensus estimates over three months is minimal and may not warrant a significant long-term strategic shift in positioning.